VHL and cancer: Leveraging the characteristic low expression of Von Hippel–Lindau (VHL) E3 ligase in human platelets [27], Dr. Zhou’s group attached a ligand for the VHL E3 ligase to two different solvent-exposed rings of ABT263, leading to the discovery of two PROTACs, DT2216 and PZ703b, which exhibit selective cytotoxicity toward cancer cells while sparing platelets, thereby preventing thrombocytopenia [27,28].